Markus Thomas Rojewski

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9223451/markus-thomas-rojewski-publications-by-year.pdf
Version: 2024-04-28

27 papers	838 citations	13 h-index	28 g-index
30 ext. papers	1,011 ext. citations	4.1 avg, IF	3.46 L-index

#	Paper	IF	Citations
27	Hexon modification of human adenovirus type 5 vectors enables efficient transduction of human multipotent mesenchymal stromal cells.. *Molecular Therapy - Methods and Clinical Development*, **2022**, 25, 96-110	6.4	0
26	Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19-Convalescent Donors. *Journal of Immunology*, **2021**, 206, 2614-2622	5.3	14
25	Transduction Enhancers Enable Efficient Human Adenovirus Type 5-Mediated Gene Transfer into Human Multipotent Mesenchymal Stromal Cells. *Viruses*, **2021**, 13,	6.2	1
24	Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing. *Journal of Infectious Diseases*, **2021**, 223, 796-801	7	32
23	Early efficacy evaluation of mesenchymal stromal cells (MSC) combined to biomaterials to treat long bone non-unions. *Injury*, **2020**, 51 Suppl 1, S63-S73	2.5	11
22	CD90 Is Dispensable for White and Beige/Brown Adipocyte Differentiation. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	1
21	Osteoarthritic Milieu Affects Adipose-Derived Mesenchymal Stromal Cells. *Journal of Orthopaedic Research*, **2020**, 38, 336-347	3.8	9
20	Translation of a standardized manufacturing protocol for mesenchymal stromal cells: A systematic comparison of validation and manufacturing data. *Cytotherapy*, **2019**, 21, 468-482	4.8	19
19	Feasibility and safety of treating non-unions in tibia, femur and humerus with autologous, expanded, bone marrow-derived mesenchymal stromal cells associated with biphasic calcium phosphate biomaterials in a multicentric, non-comparative trial. *Biomaterials*, **2019**, 196, 100-108	15.6	56
18	A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow. *Cancer Research*, **2018**, 78, 129-142	10.1	31
17	Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial. *Stem Cell Research and Therapy*, **2018**, 9, 213	8.3	74
16	Systemic recovery and therapeutic effects of transplanted allogenic and xenogenic mesenchymal stromal cells in a rat blunt chest trauma model. *Cytotherapy*, **2018**, 20, 218-231	4.8	6
15	ATP promotes immunosuppressive capacities of mesenchymal stromal cells by enhancing the expression of indoleamine dioxygenase. *Immunity, Inflammation and Disease*, **2018**, 6, 448-455	2.4	7
14	Autologous Mesenchymal Stroma Cells Are Superior to Allogeneic Ones in Bone Defect Regeneration. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	12
13	Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. *Cytotherapy*, **2015**, 17, 128-39	4.8	91
12	Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. *International Journal of Cancer*, **2015**, 137, 2083-92	7.5	14
11	S100A4 and uric acid promote mesenchymal stromal cell induction of IL-10+/IDO+ lymphocytes. *Journal of Immunology*, **2014**, 192, 6102-10	5.3	33

10	TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds. *Journal of Investigative Dermatology*, **2014**, 134, 526-537	4.3	153
9	Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. *Cytotherapy*, **2012**, 14, 540-54	4.8	207
8	Efficiency of Leukemic Stem Cell Separation From Patients with Acute Myeloid Leukemia. *Blood*, **2011**, 118, 4997-4997	2.2	1
7	Peptide Vaccination Induces Dynamic Changes in CD4+ and CD8+ T Cell Subsets: Report on the First Peptide Vaccination Trial in Patients with Chronic Lymphocytic Leukemia (CLL). *Blood*, **2008**, 112, 3159-3159	2.2	2
6	Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.. *Blood*, **2007**, 110, 1806-1806	2.2	1
5	Imatinib Inhibits Both CD4+ T Regulatory Cells and CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168.. *Blood*, **2006**, 108, 2201-2201	2.2	
4	RHAMM/CD168-R3 Peptide Vaccination of Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM) Elicits Immunological and Clinical Responses.. *Blood*, **2006**, 108, 409-409	2.2	
3	Corrigendum to: Depolarisation of the plasma membrane in the arsenic trioxide (As2O3)- and anti-CD95-induced apoptosis in myeloid cells (FEBS 29005) [FEBS Letters 578 (2004) 85□89]. *FEBS Letters*, **2005**, 579, 3866-3866	3.8	
2	Depolarisation of the plasma membrane in the arsenic trioxide (As2O3)-and anti-CD95-induced apoptosis in myeloid cells. *FEBS Letters*, **2004**, 578, 85-9	3.8	23
1	The K+ channel openers diazoxide and NS1619 induce depolarization of mitochondria and have differential effects on cell Ca2+ in CD34+ cell line KG-1a. *Experimental Hematology*, **2003**, 31, 815-23	3.1	38